查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1776781

2032 年个人化医疗市场预测：按产品、技术、应用、最终用户和地区进行的全球分析

Personalized Medicine Market Forecasts to 2032 - Global Analysis By Product, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球个人化医疗市场预计在 2025 年达到 6,428 亿美元，到 2032 年将达到 1,2,686 亿美元，预测期内的复合年增长率为 10.2%。

个人化医疗，又称精准医疗，是一种根据个人遗传、环境和生活方式因素量身定制治疗和预防策略的医疗方法。它利用基因组学、诊断学和数据分析领域的进步来预测疾病风险、选择最佳治疗方法并改善患者预后。与传统的「一刀切」模式不同，个人化医疗可以提高药物疗效、减少副作用并支持早期发现。它透过在肿瘤学、心臟病学和罕见遗传疾病等领域实现标靶治疗，正在改变医疗保健领域。

增加对标靶治疗和研发的投资

由于针对个别患者特征的标靶治疗投入不断增加，个人化医疗市场正在经历显着成长。基因组学研究的进展使得针对各种疾病的精准治疗成为可能。公共和私营部门的资金投入不断增加，加速了个人化医疗技术的创新。製药公司和研究机构之间的合作正在催生突破性的个人化治疗方案。此外，政府支持精准医疗研究的措施也进一步推动了市场的扩张。

个人化医疗保健的保险覆盖范围有限

个人化医疗诊断和治疗的高昂成本，是其广泛应用的一大障碍。许多保险公司限制对高级基因组检测和标靶治疗的承保，增加了患者的自付费用。个人化医疗服务缺乏标准化的报销政策，为病患和医疗服务提供者都带来了经济挑战。这些经济负担可能会阻碍患者接受个人化医疗，并限制市场成长。努力扩大保险覆盖范围并简化报销流程，对于克服这项限制至关重要。

药物基因组学和伴随诊断的发展

药物基因体学的兴起创造了新的机会，它能够根据个体基因图谱实现个人化药物治疗。伴随诊断因其能够更准确地预测治疗效果和安全性而日益普及。预防性医疗保健的日益普及，推动了对药物基因体学检测的需求，从而优化了药物处方。在新兴市场，医疗基础设施的改善正在推动伴随诊断的应用激增。此外，人工智慧和数据分析的进步也提高了这些诊断工具的准确性和可近性。

医疗保健IT基础设施缺乏互通性

缺乏标准化的医疗IT系统阻碍了个人化医疗数据跨平台的无缝整合。不一致的数据格式和通讯协定使医疗服务提供者之间共用关键患者资讯变得复杂。缺乏互通性导致诊断和治疗计画效率低下，影响患者治疗效果。升级传统IT系统以支援个人化医疗应用的高成本构成了重大挑战。如果没有统一的标准，个人化医疗解决方案的扩充性将仍然有限，从而威胁市场成长。

COVID-19的影响：

新冠疫情扰乱了个人化医疗市场，导致非必要的诊断程序和临床试验被推迟。然而，疫情也加速了远端医疗的普及，使远距会诊能够制定个人化治疗方案。这场危机凸显了快速基因序列测定在标靶治疗开发中的重要性，并促进了该领域的研究。供应链中断暂时影响了诊断工具和试剂的供应。疫情后的復苏预计将进一步凸显精准诊断在感染疾病和慢性病管理中的作用。

个人化医疗诊断领域预计将成为预测期内最大的领域

由于对精准早期疾病检测的需求日益增长，个人化医疗诊断领域预计将在预测期内占据最大的市场占有率。基因组定序技术的进步使得更精准的诊断工具能够用于个人化治疗。医疗保健提供者对个人化诊断益处的认识不断提高，推动了其应用。研发投入正在催生更精准、更具创新性的诊断平台。此外，政府的支持性政策和对精准医疗计画的资助也推动了该领域的成长。

预计预测期内肿瘤学领域将以最高的复合年增长率成长。

预计肿瘤学领域将在预测期内实现最高成长率，这得益于全球癌症发生率的上升以及对标靶治疗的需求。基因组分析的创新使得针对每位患者量身定制的精准肿瘤治疗成为可能。癌症研究资金的增加促进了个人化癌症诊断和治疗方法的进步。癌症研究中心和製药公司之间的合作正在推动市场成长。此外，人们对早期癌症检测意识的不断提高也推动了对个人化肿瘤学解决方案的需求。

占比最大的地区：

预计亚太地区将在预测期内占据最大的市场占有率，这得益于中国和印度等国家医疗基础设施的快速改善。该地区慢性病的盛行率不断上升，推动了对个人化医疗解决方案的需求。政府旨在推广精准医疗和解决医疗差距的措施正在推动市场成长。医疗支出的增加和患者对个人化治疗意识的增强是关键因素。此外，与全球製药公司的合作也正在增强人们获得先进个人化医疗技术的管道。

复合年增长率最高的地区：

预计北美将在预测期内实现最高的复合年增长率，这得益于其完善的医疗基础设施和对精准医疗研究的大量投资。大型製药和生物技术公司的涌现正在推动个人化医疗解决方案的创新。医疗保健提供者和患者对个人化治疗益处的认识不断提高，也是主要的成长动力。

提供免费客製化：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第五章全球个人化医疗市场（按产品）

  • 个性化医疗诊断
    • 基因检测
    • 直接面向消费者 (DTC) 的诊断
    • 深奥化验服务
    • 困难的实验室筛检
  • 个人化医疗
    • 製药
    • 基因组医学
    • 医疗设备
  • 个人化医疗
    • 远端医疗
    • 医疗资讯技术
  • 个人化营养与健康
    • 零售营养
    • 补充和替代医学

6. 全球个人化医疗市场（按技术）

  • 巨量资料分析
  • 人工智慧
  • 生物资讯学
  • 基因序列分析
  • 药物研发
  • 其他技术

7. 全球个人化医疗市场（按应用）

  • 肿瘤学
  • 中枢神经系统
  • 免疫学
  • 呼吸系统
  • 肝
  • 风湿病
  • 其他用途

第八章全球个人化医疗市场（依最终用户）

  • 医院
  • 诊断中心
  • 研究和学术机构
  • 其他最终用户

9. 全球个人化医疗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十章：主要发展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十一章 公司概况

  • GE Healthcare
  • Illumina, Inc.
  • ASURAGEN, INC.
  • Abbott
  • Dako A/S
  • Exact Sciences Corporation
  • Danaher Corporation（Cepheid, Inc.）
  • Decode Genetics, Inc.
  • QIAGEN
  • Exagen Inc.
  • Precision Biologics
  • Celera Diagnostics LLC.
  • Biogen
  • Genelex
  • International Business Machines Corporation（IBM）
  • Genentech, Inc.
  • 23andMe, Inc.
Product Code: SMRC30112

According to Stratistics MRC, the Global Personalized Medicine Market is accounted for $642.8 billion in 2025 and is expected to reach $1268.6 billion by 2032 growing at a CAGR of 10.2% during the forecast period. Personalized Medicine, also known as precision medicine, is a medical approach that tailors treatment and prevention strategies to individual genetic, environmental, and lifestyle factors. It leverages advances in genomics, diagnostics, and data analytics to predict disease risks, select optimal therapies, and improve patient outcomes. Unlike traditional one-size-fits-all models, personalized medicine enhances drug efficacy, reduces side effects, and supports early detection. It is transforming healthcare by enabling targeted treatments in fields like oncology, cardiology, and rare genetic disorders.

Market Dynamics:

Driver:

Growing investment in targeted therapies and R&D

The personalized medicine market is experiencing significant growth due to increased investments in targeted therapies tailored to individual patient profiles. Advancements in genomic research are enabling the development of precision treatments for various diseases. Rising funding from both public and private sectors is accelerating innovation in personalized medicine technologies. Collaborative efforts between pharmaceutical companies and research institutions are fostering breakthroughs in personalized treatment options. Additionally, government initiatives supporting precision medicine research are further propelling market expansion.

Restraint:

Limited insurance coverage for personalized healthcare

The high cost of personalized medicine diagnostics and treatments poses a significant barrier to widespread adoption. Many insurance providers offer limited coverage for advanced genomic testing and targeted therapies, increasing out-of-pocket expenses for patients. The lack of standardized reimbursement policies for personalized healthcare services creates financial challenges for both patients and providers. This financial burden can discourage patients from seeking personalized care, limiting market growth. Efforts to expand insurance coverage and streamline reimbursement processes are critical to overcoming this restraint.

Opportunity:

Growth in pharmacogenomics and companion diagnostics

The rise of pharmacogenomics is creating new opportunities by enabling tailored drug therapies based on individual genetic profiles. Companion diagnostics are gaining traction, allowing for more accurate prediction of treatment efficacy and safety. The growing emphasis on preventive healthcare is boosting demand for pharmacogenomic testing to optimize drug prescriptions. Emerging markets are witnessing a surge in adoption of companion diagnostics due to improving healthcare infrastructure. Additionally, advancements in AI and data analytics are enhancing the precision and accessibility of these diagnostic tools.

Threat:

Lack of interoperability in healthcare IT infrastructure

The absence of standardized healthcare IT systems hinders seamless integration of personalized medicine data across platforms. Inconsistent data formats and protocols complicate the sharing of critical patient information among healthcare providers. This lack of interoperability can lead to inefficiencies in diagnosis and treatment planning, impacting patient outcomes. The high cost of upgrading legacy IT systems to support personalized medicine applications poses a significant challenge. Without unified standards, the scalability of personalized medicine solutions remains limited, threatening market growth.

Covid-19 Impact:

The COVID-19 pandemic disrupted the personalized medicine market by delaying non-essential diagnostic procedures and clinical trials. However, it accelerated the adoption of telemedicine, enabling remote consultations for personalized treatment plans. The crisis highlighted the importance of rapid genetic sequencing for developing targeted therapies, boosting research in this area. Supply chain disruptions temporarily affected the availability of diagnostic tools and reagents. Post-pandemic recovery is expected to further emphasize the role of precision diagnostics in managing infectious and chronic diseases.

The personalized medicine diagnostics segment is expected to be the largest during the forecast period

The personalized medicine diagnostics segment is expected to account for the largest market share during the forecast period, owing to the increasing demand for accurate and early disease detection. Advancements in genomic sequencing technologies are enabling more precise diagnostic tools for tailored treatments. Rising awareness among healthcare providers about the benefits of personalized diagnostics is driving adoption. Investments in research and development are leading to innovative diagnostic platforms with higher accuracy. Additionally, supportive government policies and funding for precision medicine initiatives are bolstering this segment's growth.

The oncology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the oncology segment is predicted to witness the highest growth rate, impelled by the rising incidence of cancer globally and the need for targeted therapies. Innovations in genomic profiling are enabling the development of precision oncology treatments tailored to individual patients. Increased funding for cancer research is driving advancements in personalized cancer diagnostics and therapies. Collaborative efforts between oncology research centers and pharmaceutical companies are accelerating market growth. Furthermore, heightened awareness of early cancer detection is boosting demand for personalized oncology solutions.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rapid improvements in healthcare infrastructure across countries like China and India. The increasing prevalence of chronic diseases in the region is boosting demand for personalized medicine solutions. Government initiatives aimed at promoting precision medicine and reducing healthcare disparities are fueling market growth. Rising healthcare expenditure and growing awareness of personalized treatments among patients are key contributors. Additionally, collaborations with global pharmaceutical companies are enhancing access to advanced personalized medicine technologies.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to, its well-established healthcare infrastructure and significant investments in precision medicine research. The presence of leading pharmaceutical and biotechnology companies drives innovation in personalized medicine solutions. Increasing awareness among healthcare providers and patients about the benefits of personalized treatments is a key growth driver.

Key players in the market

Some of the key players in Personalized Medicine Market include GE Healthcare, Illumina, Inc., ASURAGEN, INC., Abbott, Dako A/S, Exact Sciences Corporation, Danaher Corporation (Cepheid, Inc.), Decode Genetics, Inc., QIAGEN, Exagen Inc., Precision Biologics, Celera Diagnostics LLC., Biogen, Genelex, International Business Machines Corporation (IBM), Genentech, Inc., and 23andMe, Inc.

Key Developments:

In May 2025, Illumina and Ovation.io introduced a groundbreaking GLP-1 multi-omic dataset encompassing 25,000 patient profiles. This initiative aims to accelerate precision medicine by enhancing drug response prediction, enabling researchers to refine targeted therapies using integrated genomic, proteomic, and metabolomic insights.

In May 2025, Illumina expanded its clinical oncology offerings by launching the Pillar oncoReveal(R)CDx panel. This companion diagnostic tool supports personalized cancer therapy, offering broader access to genomic profiling and enabling clinicians to align treatments more effectively with patients' tumor-specific genetic mutations.

Products Covered:

  • Personalized Medicine Diagnostics
  • Personalized Medicine Therapeutics
  • Personalized Medical Care
  • Personalized Nutrition and Wellness

Technologies Covered:

  • Big Data Analytics
  • Artificial Intelligence
  • Bioinformatics
  • Gene Sequencing
  • Drug Discovery
  • Other Technologies

Applications Covered:

  • Oncology
  • CNS
  • Immunology
  • Respiratory
  • Liver
  • Rheumatology
  • Other Applications

End Users Covered:

  • Hospitals
  • Diagnostic Centers
  • Research & Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Medicine Market, By Product

  • 5.1 Introduction
  • 5.2 Personalized Medicine Diagnostics
    • 5.2.1 Genetic Testing
    • 5.2.2 Direct-To-Consumer (DTC) Diagnostics
    • 5.2.3 Esoteric Lab Services
    • 5.2.4 Esoteric Lab Tests
  • 5.3 Personalized Medicine Therapeutics
    • 5.3.1 Pharmaceutical
    • 5.3.2 Genomic Medicine
    • 5.3.3 Medical Devices
  • 5.4 Personalized Medical Care
    • 5.4.1 Telemedicine
    • 5.4.2 Health Information Technology
  • 5.5 Personalized Nutrition & Wellness
    • 5.5.1 Retail Nutrition
    • 5.5.2 Complementary & Alternative Medicine

6 Global Personalized Medicine Market, By Technology

  • 6.1 Introduction
  • 6.2 Big Data Analytics
  • 6.3 Artificial Intelligence
  • 6.4 Bioinformatics
  • 6.5 Gene Sequencing
  • 6.6 Drug Discovery
  • 6.7 Other Technologies

7 Global Personalized Medicine Market, By Application

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 CNS
  • 7.4 Immunology
  • 7.5 Respiratory
  • 7.6 Liver
  • 7.7 Rheumatology
  • 7.8 Other Applications

8 Global Personalized Medicine Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Diagnostic Centers
  • 8.4 Research & Academic Institutes
  • 8.5 Other End Users

9 Global Personalized Medicine Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 GE Healthcare
  • 11.2 Illumina, Inc.
  • 11.3 ASURAGEN, INC.
  • 11.4 Abbott
  • 11.5 Dako A/S
  • 11.6 Exact Sciences Corporation
  • 11.7 Danaher Corporation (Cepheid, Inc.)
  • 11.8 Decode Genetics, Inc.
  • 11.9 QIAGEN
  • 11.10 Exagen Inc.
  • 11.11 Precision Biologics
  • 11.12 Celera Diagnostics LLC.
  • 11.13 Biogen
  • 11.14 Genelex
  • 11.15 International Business Machines Corporation (IBM)
  • 11.16 Genentech, Inc.
  • 11.17 23andMe, Inc.

List of Tables

  • Table 1 Global Personalized Medicine Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Personalized Medicine Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Personalized Medicine Market Outlook, By Personalized Medicine Diagnostics (2024-2032) ($MN)
  • Table 4 Global Personalized Medicine Market Outlook, By Genetic Testing (2024-2032) ($MN)
  • Table 5 Global Personalized Medicine Market Outlook, By Direct-To-Consumer (DTC) Diagnostics (2024-2032) ($MN)
  • Table 6 Global Personalized Medicine Market Outlook, By Esoteric Lab Services (2024-2032) ($MN)
  • Table 7 Global Personalized Medicine Market Outlook, By Esoteric Lab Tests (2024-2032) ($MN)
  • Table 8 Global Personalized Medicine Market Outlook, By Personalized Medicine Therapeutics (2024-2032) ($MN)
  • Table 9 Global Personalized Medicine Market Outlook, By Pharmaceutical (2024-2032) ($MN)
  • Table 10 Global Personalized Medicine Market Outlook, By Genomic Medicine (2024-2032) ($MN)
  • Table 11 Global Personalized Medicine Market Outlook, By Medical Devices (2024-2032) ($MN)
  • Table 12 Global Personalized Medicine Market Outlook, By Personalized Medical Care (2024-2032) ($MN)
  • Table 13 Global Personalized Medicine Market Outlook, By Telemedicine (2024-2032) ($MN)
  • Table 14 Global Personalized Medicine Market Outlook, By Health Information Technology (2024-2032) ($MN)
  • Table 15 Global Personalized Medicine Market Outlook, By Personalized Nutrition & Wellness (2024-2032) ($MN)
  • Table 16 Global Personalized Medicine Market Outlook, By Retail Nutrition (2024-2032) ($MN)
  • Table 17 Global Personalized Medicine Market Outlook, By Complementary & Alternative Medicine (2024-2032) ($MN)
  • Table 18 Global Personalized Medicine Market Outlook, By Technology (2024-2032) ($MN)
  • Table 19 Global Personalized Medicine Market Outlook, By Big Data Analytics (2024-2032) ($MN)
  • Table 20 Global Personalized Medicine Market Outlook, By Artificial Intelligence (2024-2032) ($MN)
  • Table 21 Global Personalized Medicine Market Outlook, By Bioinformatics (2024-2032) ($MN)
  • Table 22 Global Personalized Medicine Market Outlook, By Gene Sequencing (2024-2032) ($MN)
  • Table 23 Global Personalized Medicine Market Outlook, By Drug Discovery (2024-2032) ($MN)
  • Table 24 Global Personalized Medicine Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 25 Global Personalized Medicine Market Outlook, By Application (2024-2032) ($MN)
  • Table 26 Global Personalized Medicine Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 27 Global Personalized Medicine Market Outlook, By CNS (2024-2032) ($MN)
  • Table 28 Global Personalized Medicine Market Outlook, By Immunology (2024-2032) ($MN)
  • Table 29 Global Personalized Medicine Market Outlook, By Respiratory (2024-2032) ($MN)
  • Table 30 Global Personalized Medicine Market Outlook, By Liver (2024-2032) ($MN)
  • Table 31 Global Personalized Medicine Market Outlook, By Rheumatology (2024-2032) ($MN)
  • Table 32 Global Personalized Medicine Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 33 Global Personalized Medicine Market Outlook, By End User (2024-2032) ($MN)
  • Table 34 Global Personalized Medicine Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 35 Global Personalized Medicine Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 36 Global Personalized Medicine Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 37 Global Personalized Medicine Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.